Bio-Techne Corp is a biotechnology company that specializes in developing and producing high-quality biotechnology tools and reagents for the life sciences market. The company offers a wide range of products, including proteins, antibodies, assays, and diagnostic tools, which are used by researchers and clinical laboratories for various applications, such as drug development, diagnostics, and disease research. With a focus on innovation, Bio-Techne aims to provide cutting-edge solutions that enhance research capabilities and improve patient outcomes in healthcare. Read More
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne (NASDAQ:TECH) stock moved
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash.
What Happened? Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 5.4% in the morning session after TD Cowen reiterated a Buy rating and a $65.0...
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
Over the past six months, Bio-Techne’s stock price fell to $51.95. Shareholders have lost 13.8% of their capital, which is disappointing considering the S&P ...
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade...
Bio-Techne’s first quarter was marked by a negative market reaction, with revenue coming in below Wall Street expectations. Management attributed the shortfa...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Life sciences company Bio-Techne (NASDAQ:TECH) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 1.5% year on year to $311.4 million...
